Outlook Therapeutics, Inc.
General ticker "OTLK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $54.2M (TTM average)
Outlook Therapeutics, Inc. follows the US Stock Market performance with the rate: 2.6%.
Estimated limits based on current volatility of 5.4%: low 1.79$, high 1.99$
Factors to consider:
- Total employees count: 83 as of 2016
- Current price 16.7% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [3.13$, 10.29$]
- 2025-09-30 to 2026-09-30 estimated range: [2.47$, 8.28$]
Financial Metrics affecting the OTLK estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -64.80 <= 0.33
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -20.43 <= 0
- Negative: Shareholder equity ratio, % of -253.53 <= 18.93
Short-term OTLK quotes
Long-term OTLK plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $63.07MM | $53.13MM | $71.70MM |
| Operating Income | $-63.07MM | $-53.13MM | $-71.70MM |
| Non-Operating Income | $-2.98MM | $-5.85MM | $-3.66MM |
| Interest Expense | $1.49MM | $1.56MM | $3.16MM |
| R&D Expense | $42.33MM | $26.45MM | $41.76MM |
| Income(Loss) | $-66.05MM | $-58.98MM | $-75.36MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-66.05MM | $-58.98MM | $-75.37MM |
| Stockholders Equity | $8.74MM | $-14.44MM | $-73.08MM |
| Assets | $28.53MM | $32.30MM | $28.82MM |
| Operating Cash Flow | $-56.67MM | $-42.97MM | $-68.79MM |
| Financing Cash Flow | $59.59MM | $48.97MM | $60.33MM |
| Earnings Per Share** | $-6.23 | $-4.72 | $-4.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.